Background
NCCN guidelines state that chemotherapies for esophageal and gastric carcinomas may be used interchangeably. We interrogated biomarkers from a large cohort of gastroesophageal cancer patients to identify similar and different alterations with therapeutic implications for gastric and esophageal cancers.
Miura JT, Xiu, J, Johnston FM, Turaga KK, Gamblin TC